Compare DMRC & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | MXCT |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 160.0M |
| IPO Year | N/A | 2021 |
| Metric | DMRC | MXCT |
|---|---|---|
| Price | $6.83 | $1.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $7.50 |
| AVG Volume (30 Days) | 172.1K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $33,663,000.00 | ★ $34,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.63 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.35 | $1.26 |
| 52 Week High | $48.32 | $5.20 |
| Indicator | DMRC | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 53.02 |
| Support Level | $6.51 | $1.48 |
| Resistance Level | $8.61 | $1.65 |
| Average True Range (ATR) | 0.58 | 0.08 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 8.15 | 78.38 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.